TCM
BHVN

Tygh Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Tygh Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$4.05M Buy
29,360
+163
+0.6% +$20.7K 0.52% 69
2021
Q3 		$4.06M Buy
29,197
+389
+1% +$48.6K 0.55% 73
2021
Q2 		$2.8M Sell
28,808
-294
-1% -$23.9K 0.38% 82
2021
Q1 		$1.99M Buy
29,102
+1,158
+4% +$93.7K 0.28% 83
2020
Q4 		$2.4M Buy
27,944
+619
+2% +$52.5K 0.37% 83
2020
Q3 		$1.78M Buy
+27,325
New +$1.79M 0.34% 80

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tygh Capital Management's BHVN Position: Q4 2021 in Review

Tygh Capital Management increased its Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stake by 0.56% in Q4 2021, buying an estimated $20.7K and bringing the position to 29,360 shares worth $4.05M. The position accounts for 0.52% of the portfolio, ranked #69.

Tygh Capital Management first reported a position in BHVN in Q3 2020 and has held it in 6 quarters since. The position peaked at $4.06M in Q3 2021. 284 funds tracked by Wall St. Rank hold BHVN as of Q4 2021.

  • Tygh Capital Management held 29,360 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $4.05M as of Q4 2021.
  • Tygh Capital Management bought 163 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2021, an estimated $20.7K.
  • Biohaven Pharmaceutical Holding Company Ltd. made up 0.52% of Tygh Capital Management's portfolio in Q4 2021, its #69 holding.
  • Tygh Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2020 and has held it in 6 quarters since.
  • Tygh Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $4.06M in Q3 2021.
  • 284 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.